#GoBlue

1/n 🔥Hot off the press🔥 HyCRT-SABR for unresectable locally advanced #NSCLC in JAMA Oncology! Tweetorial of key findings and historical perspective. #radonc ASTRO IASLC Society for Immunotherapy of Cancer The ASCO Post The Society of Thoracic Surgeons the Radiosurgery Society City of Hope Surgery OncoAlert Stan Liauw WomenInThoracicSurg

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology – work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

A must listen on the physical/mental/spiritual stresses physicians must endure - and learn how to handle - during their career journey while striving to heal their patients. twitter.us16.list-manage.com/track/click?u=…

Beautiful ⁦Journal of Clinical Oncology⁩ piece that resonated with my 10 yrs in #rural #oncology. The patients (and their families) with whom I worked were the kindest and most grateful in my career. I was lucky to be a part of their journey. ascopubs.org/doi/10.1200/OP…

Reconciling the discrepancies in randomized data of combining immunotherapy and radiation therapy: Not all radiotherapy is created equal, published in Europe Journal of Cancer today. Here is the personalized Share Link: authors.elsevier.com/a/1ihIj_Lqip9w…

Excellent and concise NEJM editorial on the theoretical benefits and actual risks of health care vertical integration. nejm.org/doi/full/10.10…

A thoughtful oncologist perspective in JAMA Oncology on what it can feel like at a time of a potential oncologic diagnosis and that even the most favorable prognosis does not bring much comfort. jamanetwork.com/journals/jamao…

Wendy Woodward MDPhD One thing is for sure, I’d be less likely to omit RT for low ER+! 10y local failure of 18.8% on PRIME2 😳 (read: most favorable candidates for omission. >= 65y, < 3 cm (only 10% 2-3 cm), pN0, SM >= 1mm, G1-2 (only 3% G3), LVSI (4%), G3 AND LVSI excluded)

🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine +/- erlotinib (no benefit with erlotinib) 🔥2nd Randomization🔥 +/- Chemoradiation, 50.4 Gy/28 fx + cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #asco24

⁦An insightful The Wall Street Journal⁩ perspective piece on #financialtoxicity for #oncology patients. wsj.com/health/healthc…

ADRIATIC study is the new standard of care for limited stage small cell lung cancer followed by adjuvant durvalumab with improved mOS to 56 mo from 33 mo (placebo) and mPFS of 17 months with durvalumab vs 9 mo (placebo) #ASCO24

Absolutely terrific thread here on ENI dosing for oropharyngeal cancer, touching not just on recent data but on how new standards are established. Just a few thoughts on top of well-articulated arguments for different approaches. (1/n)

Fascinating news regarding #xevinapant in #hncsm emdgroup.com/en/news/xevina…

So proud of my former colleagues Cleveland Clinic co-residents, & med school classmates University of Michigan honored at #ASTRO24!

Brilliant JCO Oncology Practice perspective piece by the estimable Rahul Tendulkar, MD on how to find the right meaning & balance in medical practice today. This advice translates to life & #leadership in general, so a must read for all. #medicine #goldenrule #empathy ascopubs.org/doi/full/10.12…

Young Doctors Want Work-Life Balance. Older Doctors Say That’s Not the Job. - #WSJ wsj.com/lifestyle/care…

Presented at #SABCS24: Interim results from the EUROPA trial: Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer thelancet.com/journals/lanon…

Thank you to our 🔥 panelists! Dr. Sushil Beriwal, Tom Boike, Kiran Devisetty, MD, FASTRO, & Trevor J. Royce MD MPH FASCO. Amazing insight into careers in industry and the overlap with clinical roles. We are still clinicians at the end of the day! 🥼 Had so much fun moderating!! ARRO ASTRO #ARRODay